These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. ALERT: mix-ups between conventional and lipid formulations of amphotericin B can be extremely dangerous. Koczmara C, Richardson H, Hyland S, Lee CS, Hillebrand N. Dynamics; 2011; 22(1):24-6. PubMed ID: 21469498 [Abstract] [Full Text] [Related]
27. Liposomal formulations of amphotericin B: differences according to the scientific evidence. Azanza JR, Sádada B, Reis J. Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170 [Abstract] [Full Text] [Related]
28. Reply to Messori et al. Mistro S, Schooley RT, Badaro R. Clin Infect Dis; 2013 Dec; 57(12):1784-5. PubMed ID: 24140973 [No Abstract] [Full Text] [Related]
38. Lipid formulations of amphotericin B: recent progress and future directions. Hiemenz JW, Walsh TJ. Clin Infect Dis; 1996 May; 22 Suppl 2():S133-44. PubMed ID: 8722841 [Abstract] [Full Text] [Related]
39. Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens. Adler-Moore JP, Proffitt RT, Olson JA, Jensen GM. J Liposome Res; 2017 Sep; 27(3):195-209. PubMed ID: 28480760 [Abstract] [Full Text] [Related]
40. Lipid formulations of amphotericins: are you a lumper or a splitter? Wingard JR. Clin Infect Dis; 2002 Oct 01; 35(7):891-5. PubMed ID: 12228829 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]